SNPHF OTC
Santen Pharmaceutical Co., Ltd.
1W: +1.0%
1M: +0.0%
3M: +0.0%
YTD: +37.2%
1Y: +14.0%
3Y: +44.7%
5Y: -3.3%
$13.05
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Balance Sheet Trends
Total Assets
$425.7B
+4.0% ▲
5Y CAGR: +1.1%
Total Liabilities
$127.8B
+3.0% ▲
5Y CAGR: +6.0%
Shareholders Equity
$298.9B
+4.4% ▲
5Y CAGR: -0.6%
Cash & Investments
$83.3B
-11.3% ▼
5Y CAGR: +5.6%
Total Debt
$34.8B
+1.5% ▲
5Y CAGR: +27.9%
Net Debt
-$45.9B
+50.6% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $83.0B | $57.9B | $94.6B | $93.0B | $80.9B |
| Short-Term Investments | $1.3B | $774M | $379M | $997M | $2.5B |
| Cash & ST Investments | $84.3B | $58.7B | $95.0B | $94.0B | $83.3B |
| Net Receivables | $99.6B | $107.2B | $90.5B | $71.8B | $72.3B |
| Inventory | $37.1B | $39.4B | $43.2B | $51.6B | $65.0B |
| Other Current Assets | $8.4B | $8.1B | $7.5B | $7.0B | $9.6B |
| Total Current Assets | $229.4B | $213.3B | $236.1B | $224.3B | $230.2B |
| Property, Plant & Equip. | $56.3B | $66.2B | $71.6B | $73.0B | $78.6B |
| Goodwill & Intangibles | $130.2B | $96.3B | $83.8B | $75.5B | $72.1B |
| Long-Term Investments | $40.9B | $36.6B | $24.4B | $26.5B | $20.1B |
| Other Non-Current Assets | $0 | $6.0B | $19.8B | $1M | $13.8B |
| Total Non-Current Assets | $230.6B | $207.9B | $199.6B | $185.0B | $195.5B |
| Total Assets | $460.0B | $421.2B | $435.7B | $409.3B | $425.7B |
| — Liabilities — | |||||
| Accounts Payable | $41.2B | $44.9B | $43.5B | $39.0B | $35.6B |
| Short-Term Debt | $10.9B | $245M | $54M | $274M | $306M |
| Deferred Revenue | -$14.0B | -$3.1B | $0 | $0 | $0 |
| Other Current Liabilities | $54.6B | $44.6B | $38.7B | $42.3B | $44.8B |
| Total Current Liabilities | $95.8B | $89.5B | $92.8B | $86.8B | $88.4B |
| Long-Term Debt | $12.7B | $28.2B | $0 | $0 | $0 |
| Other Non-Current Liab. | $24.8B | $36.8B | $35.4B | $34.7B | $34.8B |
| Total Non-Current Liabilities | $27.3B | $38.4B | $37.5B | $37.3B | $39.1B |
| Total Liabilities | $123.1B | $127.9B | $130.3B | $124.1B | $127.8B |
| — Equity — | |||||
| Common Stock | $8.7B | $8.7B | $8.8B | $8.8B | $8.9B |
| Retained Earnings | $290.5B | $238.1B | $240.0B | $228.3B | $224.7B |
| Accumulated OCI | $29.7B | $37.8B | $48.4B | $40.5B | $56.6B |
| Total Stockholders Equity | $337.5B | $294.0B | $306.1B | $286.2B | $298.9B |
| Total Liabilities & Equity | $460.6B | $421.9B | $435.7B | $409.3B | $425.7B |
| — Key Metrics — | |||||
| Total Debt | $32.9B | $36.2B | $35.2B | $34.2B | $34.8B |
| Net Debt | -$50.1B | -$21.7B | -$59.4B | -$93.0B | -$45.9B |
| Total Investments | $42.2B | $37.4B | $24.8B | $27.5B | $20.1B |